Nasodine Nasal Spray phase 3 clinical trial : Firebrick Pharma completes 82% patient recruitment

Firebrick Pharma, an ASX-listed pharmaceutical company, announced that it has successfully enrolled 160 subjects in the confirmatory phase 3 clinical trial of Nasodine Nasal Spray ... Read More